Immunomic Therapeutics

118 articles about Immunomic Therapeutics

• Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2021

  4/27/2021

  Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021. CEO and Co-Founder Bill Hearl, Ph.D., will present a talk titled, “Adaptive T-cell immunotherapy for newly diagnosed glioblastoma: Using targeted antigen presentation to enhance immune responses,” at 15:00 on May 4, 2021.

• Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

  4/20/2021

  Lineage to Receive $2 Million Upfront and up to $67 Million in Development and Commercial Milestones Plus Royalties Partnership Leverages the VAC Allogeneic Cancer Immunotherapy Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

• Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

  4/20/2021

  Partnership Leverages Lineage’s Investigational VAC Allogeneic Cancer Vaccine Platform and Immunomic’s Proprietary Tumor Associated Antigen to Generate a Novel Oncology Product Candidate

• Immunomic Therapeutics’ CEO to present at the BIO CEO & Investor Digital Conference

  2/2/2021

  Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the BIO CEO & Investor Digital Conference, February 16-18, 2021.

• Immunomic Therapeutics’ CEO to present at the 13th Annual Biotech Showcase Digital Event

  1/5/2021

  Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 13 th Annual Biotech Showcase Digital Event, January 11-15, 2021. Chief Executive Officer at ITI, Dr. Bill Hearl, will present a talk titled, “ITI-1000-A Novel Immunotherapy for GBM.” Dr. Hearl will discuss ITI’s investigational UNiversal Intracellular Targeted Expression (UNITE)

• Immunomic Therapeutics Executives and Board Members of WhyWeVax™ Discuss COVID-19 Vaccine Issues with Fox News and CDC’s ACIP Committee

  12/9/2020

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, and WhyWeVax™ (WWV), announced that executives from both organizations recently made public comments discussing the science of COVID-19 vaccines and the challenges of vaccine hesitancy and distribution.

• Immunomic Therapeutics’ CEO to Present at the 2nd Annual Glioblastoma Drug Development Summit

  12/1/2020

  Immunomic Therapeutics, Inc. (ITI) announced today that it will be presenting at the 2nd Annual Glioblastoma Drug Development Virtual Summit. On Wednesday, December 9th, Chief Executive Officer at ITI, Dr. Bill Hearl, will be presenting a talk titled, “Adaptive T-cell Immunotherapy for Newly Diagnosed Glioblastoma: Using Targeted Antigen Presentation to Enhance Immune Responses.

• Immunomic Therapeutics and CoImmune Therapeutics Enter into Partnership to Manufacture ITI-1020, a Novel Experimental Cell Therapy for Glioblastoma

  11/19/2020

  Immunomic Therapeutics, Inc., (“ITI”), and CoImmune, Inc. (“CoImmune”), a privately held clinical-stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications, announced today that the companies have entered into a license agreement for ITI to use CoImmune’s proprietary dendritic cell process for certain ITI cell therapy vaccine programs

• Immunomic Therapeutics to Present at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs

  11/2/2020

  Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice.

• Immunomic Therapeutics Announces Promotion of Dr. Tim Coleman to Senior Vice President, Operations and General Manager

  10/22/2020

  Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the promotion of Dr. Tim Coleman to the newly created role of Senior Vice President, Operations and General Manager. Dr. Coleman joined ITI in 2015, and during his tenure with the company, has played a key role in managing several functional areas incl

• Immunomic Therapeutics’ CEO to Present at the 5th International Virtual Conference on Cancer Research & Development 2020

  10/20/2020

  Immunomic Therapeutics’ CEO to Present at the 5 th International Virtual Conference on Cancer Research & Development 2020

• Immunomic Therapeutics’ CEO to Participate in Panel at MD Life Sciences’ Bio Innovation Conference Meeting 2020

  9/29/2020

  Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio Innovation virtual conference in Maryland. On Monday, October 5, Chief Executive Officer at Immunomic, Dr. Bill Hearl, will participate in a panel titled, “Pandemic & Risk Mitigation: A Focus on Preparation & Resiliency” alongside Novavax’s President and CEO, Stanley Erck, and Emmes’ President, Anne Lindbl

• Immunomic Therapeutics’ VP, Clinical Development to Participate at Precision Medicine’s Webinar on Oncolytic Therapeutic Development

  9/23/2020

  Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy to promote oncolytic therapeutic development. On Thursday, September 24, Vice President of Clinical Development at Immunomic, Dr. Andrew Eisen, will be discussing methods and tools to utilize liquid biopsy to promote oncology therapeutic development alongside Akoya Biosciences’ CMO, Dr. Ge

• Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2020

  9/14/2020

  Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D., Immunomic’s Vice President of Clinical Development, will present a talk titled, “Pharmacodynamic Imaging in a CMV Vaccine Trial for Glioblastoma.” In addition, Immunomic Therapeutics, lead founder and supporter of Why We Vax

• Immunomic Therapeutics Inc. Expands into South Korea

  9/10/2020

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in South Korea.

• Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM

  9/1/2020

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that results from multiple ATTAC clinical studies of dendritic cell vaccines have been published online by American Associatio

• Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers

  6/24/2020

  -Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations-

• Immunomic Therapeutics Enters into License Agreement with Ichor Medical Systems to Use Electroporation (EP) Delivery Technology in Phase I Study of DNA Vaccine Therapy, ITI-1001

  6/16/2020

  Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”), a privately held biotech company based in San Diego, CA, announced today that the companies have entered into a license agreement to support the development of I

• Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II

  6/11/2020

  Immunomic Therapeutics, Inc. will present preclinical data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses when used with its investigational UNITE vaccine, ITI-3000, in mice. UNITE fuses a tumor-associated

• Immunomic Therapeutics Announces Appointments to its Board of Directors

  5/5/2020

  Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the appointment of five new members to its Board of Directors from HLB, Co. Ltd (“HLB”) and its HLB Bio subsidiaries. “I am delighted to welcome